Tag: Novartis
Bausch + Lomb to acquire dry eye disease medication XIIDRA from Novartis
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast ophthalmic solution) 5%, known for treating dry ... Read More
Aurobindo subsidiary gets license to develop and market Nilotinib Capsules in LMICs
Aurobindo Pharma, along with its subsidiary Eugia Pharma Specialities has announced a voluntary sub-licensing agreement with Medicines Patent Pool (MPP) to develop and market Nilotinib ... Read More
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around ... Read More
Novartis to offload US rights to five ophthalmic drugs to Harrow
Harrow Health, an ophthalmic therapies developer, will acquire the exclusive US commercial rights to five FDA‑approved ophthalmic products from the Novartis group of companies for ... Read More
Novartis gets Pluvicto EC approval for advanced prostate cancer
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy for advanced prostate cancer. Following ... Read More
Dr. Reddy’s to sell and distribute certain Novartis’ products in India
Dr. Reddy's Laboratories has signed an exclusive sales and distribution agreement with Novartis India Limited (NIL) for the latter’s Voveran range, the Calcium range and ... Read More
Novartis to acquire ocular gene therapy company Gyroscope Therapeutics
Novartis has agreed to acquire Gyroscope Therapeutics, a UK-based ocular gene therapy company, in a deal worth up to $1.5 billion. As per the terms ... Read More
Novartis gets Leqvio FDA approval for reducing bad cholesterol levels
Novartis has secured approval from the US Food and Drug Administration (FDA) for its small interfering RNA (siRNA) therapy Leqvio (inclisiran) for its use in ... Read More
Cipla gets FDA approval for generic version of Novartis’ Durezo
Cipla Limited said that it has secured final approval for its abbreviated new drug application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the US Food ... Read More
Sandoz to acquire GSK’s cephalosporin antibiotics business in $500m worth deal
Sandoz, a division of Swiss pharma giant Novartis, has agreed to acquire GSK’s cephalosporin antibiotics business in a deal worth up to $500 million. The ... Read More